Skip to main content
Top
Published in: Molecular Cancer 1/2019

Open Access 01-12-2019 | Letter to the Editor

Molecular characterization and clinical relevance of m6A regulators across 33 cancer types

Authors: Yongsheng Li, Jun Xiao, Jing Bai, Yi Tian, Yinwei Qu, Xiang Chen, Qi Wang, Xinhui Li, Yunpeng Zhang, Juan Xu

Published in: Molecular Cancer | Issue 1/2019

Login to get access

Abstract

The methylation of N6 adenosine (m6A) plays a critical role in diverse biological processes. However, knowledge regarding the reconstitution of m6A across cancer types is still lacking. Here, we systematically analyzed the molecular alterations and clinical relevance of m6A regulators across > 10,000 subjects representing 33 cancer types. We found that there are widespread genetic alterations to m6A regulators, and that their expression levels are significantly correlated with the activity of cancer hallmark-related pathways. Moreover, m6A regulators were found to be potentially useful for prognostic stratification, and we identified IGF2BP3 as a potential oncogene across multiple cancer types. Our results provide a valuable resource that will guide both mechanistic and therapeutic analyses of the role of m6A regulators in cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m (6) a decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616–24.CrossRef Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m (6) a decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616–24.CrossRef
2.
go back to reference Wang S, Chai P, Jia R, Jia R. Novel insights on m (6) a RNA methylation in tumorigenesis: a double-edged sword. Mol Cancer. 2018;17:101.CrossRef Wang S, Chai P, Jia R, Jia R. Novel insights on m (6) a RNA methylation in tumorigenesis: a double-edged sword. Mol Cancer. 2018;17:101.CrossRef
3.
go back to reference Pinello N, Sun S, Wong JJ. Aberrant expression of enzymes regulating m (6) a mRNA methylation: implication in cancer. Cancer Biol Med. 2018;15:323–34.CrossRef Pinello N, Sun S, Wong JJ. Aberrant expression of enzymes regulating m (6) a mRNA methylation: implication in cancer. Cancer Biol Med. 2018;15:323–34.CrossRef
4.
go back to reference Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187–200.CrossRef Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187–200.CrossRef
5.
go back to reference Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m (6) a RNA methylation. Nat Rev Genet. 2014;15:293–306.CrossRef Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m (6) a RNA methylation. Nat Rev Genet. 2014;15:293–306.CrossRef
6.
go back to reference Delaunay S, Frye M. RNA modifications regulating cell fate in cancer. Nat Cell Biol. 2019;21:552–9.CrossRef Delaunay S, Frye M. RNA modifications regulating cell fate in cancer. Nat Cell Biol. 2019;21:552–9.CrossRef
7.
go back to reference Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of Cancer. Cell. 2018;173:291–304 e296.CrossRef Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of Cancer. Cell. 2018;173:291–304 e296.CrossRef
8.
go back to reference Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, Abdelfattah N, Onyeagucha BC, Cui X, Lai Z, et al. Cross-talk among writers, readers, and erasers of m (6) a regulates cancer growth and progression. Sci Adv. 2018;4:eaar8263.CrossRef Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, Abdelfattah N, Onyeagucha BC, Cui X, Lai Z, et al. Cross-talk among writers, readers, and erasers of m (6) a regulates cancer growth and progression. Sci Adv. 2018;4:eaar8263.CrossRef
9.
go back to reference Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68.CrossRef Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68.CrossRef
10.
go back to reference Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, Weinstein JN, Liang H. TANRIC: an interactive open platform to explore the function of lncRNAs in Cancer. Cancer Res. 2015;75:3728–37.CrossRef Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, Weinstein JN, Liang H. TANRIC: an interactive open platform to explore the function of lncRNAs in Cancer. Cancer Res. 2015;75:3728–37.CrossRef
Metadata
Title
Molecular characterization and clinical relevance of m6A regulators across 33 cancer types
Authors
Yongsheng Li
Jun Xiao
Jing Bai
Yi Tian
Yinwei Qu
Xiang Chen
Qi Wang
Xinhui Li
Yunpeng Zhang
Juan Xu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2019
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-019-1066-3

Other articles of this Issue 1/2019

Molecular Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine